🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Final details of the President's proposed budget could stunt U.S. cancer research, risking future advances. ASCO is fighting for robust federal cancer research funding. Contact lawmakers: brnw.ch/21wT3up #ASCOAdvocacy

#ASCO25 👀 at some of these responses! 👇🏽These are patients with MSS🧊(“cold tumors”), not the MSI-High🔥(“hot tumors”). This is a big unmet need in colorectal cancer and other cancers. 🔗 meetings.asco.org/abstracts-pres… Vilastobart (XTX101) Tumor-activated CTLA4⛔️ ➕PDL1- OncoAlert

.Clifford Hudis at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever➡️brnw.ch/21wT3U4

Adjuvant Nivo in resected EC/GEJC following neoadjuvant CRT #ASCO25 🔎CheckMate 577 👉mDFS 21.8 vs 10.8 mo 👉mDMS 27 vs 14.6 mo 👉mOS 51.7 vs 35.3 mo 🧐 OS benefit in CPS ≥1, no/maybe detrimental in CPS <1 (small group..) ESMO - Eur. Oncology

Destiny-Gastric -04 provides definitive results on sequencing 2nd line therapy in advanced gastric cancer : T-Dxd SUPERIOR to Tax/Ram #asco25

Claudin 18.2-specific CAR T cells (Satri-cel) vs treatment of physician's choice (TPC) for G/GEJC #ASCO25 🔎 CT041-ST-01 phs II trial 👉ORR 30 vs 4% 👉mPFS 3.25 vs 1.77 mo 👉mOS 7.92 vs 5.49 mo 🧐 Looks effective, but not easy implement in clinical practice ESMO - Eur. Oncology

#ASCO25 DSP107➕/➖Atezo in patients with MSS colorectal cancer. Anwaar Saeed presenting. Interesting signal. WITH liver metastases. 🎯 CD47 increases post-FOLFOX. Bigger unmet need for our patients with liver metastases. OncoAlert Something to build upon. Great work! 🙌🏽

🥳 Adjuvant FOLFOX/Atezo vs FOLFOX for resected dMMR stage 3 colon cancer more positive than I expected—DFS 3 yr 0.50 ! My opinion of trial we need now: randomized neoadj ICI vs adj ICI +|- chemo vs periop ICI Excellent presentations Frank Sinicrope, MD Myriam Chalabi 🤩

CRC staging: AJCC v9 Era Past: “TNM.” Now: “TNDM” staging system, incorporating tumor deposits as independent entity. I like it. Better than N1c grouping-better reflects survival risk. Will be a learning curve though… AJCC v10 prediction: TNDM+ctDNA 🤔

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

KEYNOTE-016 Remarkable 10 year survival Treatment ended at 2 years. Only 2/88 had progression after 2 years. Congratulations to Dung Le and study team! #ASCO25 #ASCO2025

The NCTN, albeit imperfect, serves a critical role in advancing cancer care by: 1)Conducting pragmatic trials pharma/industry would never sponsor 2)Enrolling across a diverse network (>3K sites) representative of a “real world” population Great editorial Ted Hong Thomas George, MD, FACP, FASCO👏

"In 2011, at the age of 35, I was diagnosed with Stage IV colon cancer. The cancer had spread to my liver and, eventually, to both of my lungs. For four years, I received chemotherapy systemically through my chest port and injected directly to my liver through my hepatic pump.

13 yrs of surviving cancer 🔷living life to the fullest 🔷navigating others through their cancer journey 🔷telling my story to anyone who will listen 🔷 not being scared to share the bad days that I didn’t want to get out of bed 🔷losing many people I ❤️ to this disease

Kind of challenging times in Medicine right now. How do we respond? Keep doing great research. Remember that science doesn't care what you believe. It just is.

Don’t forget: many landmark trials at #ASCO25 (e.g. ATOMIC, PDIGREE, CHALLENGE) were powered by National Cancer Institute / NCTN Such studies ask high-impact, public-benefit questions that industry often won’t/can't answer. Alliance for Clinical Trials in Oncology CCTG ECOG-ACRIN Cancer Research Group NRG Oncology SWOG Cancer Research Network

Slavery was legal. Jim Crow was legal. Never limit your sense of morality to America's legal system.

Appendix cancer has quadrupled in older Millennials—TY The New York Times Nina Agrawal for covering my Lab’s new Appendix Cancer PMP Research Foundation/NIH-funded study. Stellar collab w/ UTHealth Houston School of Public Health epidemiologist Dr. Murphy! OncoAlert Annals of Int Med 📘🔗: bit.ly/447v4oF NYT 🗞️: bit.ly/3Zo6zB9

Tolerance to therapy for patients with early-onset vs average-onset locally advanced rectal ca esmogastro.org/article/S2949-… by Madison Conces, MD Smitha Krishnamurthi ESMO - Eur. Oncology Early-onset ➡️ significantly more nausea, fatigue & side effects ➡️Consider enhanced antiemetic prophylaxis

The 17 fired members of ACIP, including me, have written an article in JAMA about our experience and our concerns. jamanetwork.com/journals/jama/…